Your browser doesn't support javascript.
loading
Association of PSP phenotypes with survival: A brain-bank study.
Guasp, Mar; Molina-Porcel, Laura; Painous, Celia; Caballol, Nuria; Camara, Ana; Perez-Soriano, Alexandra; Sánchez-Gómez, Almudena; Garrido, Alicia; Muñoz, Esteban; Marti, Maria Jose; Valldeoriola, Francesc; Grau, Oriol; Gelpí, Ellen; Respondek, Gesine; Höglinger, Guenter H; Compta, Yaroslau.
Afiliação
  • Guasp M; Parkinson's Disease and Movement Disorders Unit, Neurology Service, IDIBAPS, CIBERNED (Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas: CB06/05/0018-ISCIII), ERN-RND Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain.
  • Molina-Porcel L; Neurological Tissue Bank of the Biobanc-Hospital Clinic-IDIBAPS (Institut d'Investigacions Biomèdiques August Pi i Sunyer), Barcelona, Catalonia, Spain.
  • Painous C; Parkinson's Disease and Movement Disorders Unit, Neurology Service, IDIBAPS, CIBERNED (Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas: CB06/05/0018-ISCIII), ERN-RND Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain.
  • Caballol N; Neurology Department, Hospital Moisès Broggi, Sant Joan Despí, Catalonia, Spain.
  • Camara A; Parkinson's Disease and Movement Disorders Unit, Neurology Service, IDIBAPS, CIBERNED (Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas: CB06/05/0018-ISCIII), ERN-RND Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain; Department of Medicine & Institut de Neu
  • Perez-Soriano A; Parkinson's Disease and Movement Disorders Unit, Neurology Service, IDIBAPS, CIBERNED (Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas: CB06/05/0018-ISCIII), ERN-RND Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain.
  • Sánchez-Gómez A; Parkinson's Disease and Movement Disorders Unit, Neurology Service, IDIBAPS, CIBERNED (Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas: CB06/05/0018-ISCIII), ERN-RND Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain; Department of Medicine & Institut de Neu
  • Garrido A; Parkinson's Disease and Movement Disorders Unit, Neurology Service, IDIBAPS, CIBERNED (Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas: CB06/05/0018-ISCIII), ERN-RND Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain.
  • Muñoz E; Parkinson's Disease and Movement Disorders Unit, Neurology Service, IDIBAPS, CIBERNED (Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas: CB06/05/0018-ISCIII), ERN-RND Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain; Department of Medicine & Institut de Neu
  • Marti MJ; Parkinson's Disease and Movement Disorders Unit, Neurology Service, IDIBAPS, CIBERNED (Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas: CB06/05/0018-ISCIII), ERN-RND Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain; Department of Medicine & Institut de Neu
  • Valldeoriola F; Parkinson's Disease and Movement Disorders Unit, Neurology Service, IDIBAPS, CIBERNED (Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas: CB06/05/0018-ISCIII), ERN-RND Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain; Department of Medicine & Institut de Neu
  • Grau O; Neurological Tissue Bank of the Biobanc-Hospital Clinic-IDIBAPS (Institut d'Investigacions Biomèdiques August Pi i Sunyer), Barcelona, Catalonia, Spain.
  • Gelpí E; Neurological Tissue Bank of the Biobanc-Hospital Clinic-IDIBAPS (Institut d'Investigacions Biomèdiques August Pi i Sunyer), Barcelona, Catalonia, Spain.
  • Respondek G; Department of Neurology, Technische Universität München, Munich, Germany; German Center for Neurodegenerative Diseases (DZNE) München, Munich, Germany; Department of Neurology, Hannover Medical School, Hannover, Germany.
  • Höglinger GH; Department of Neurology, Technische Universität München, Munich, Germany; German Center for Neurodegenerative Diseases (DZNE) München, Munich, Germany; Department of Neurology, Hannover Medical School, Hannover, Germany.
  • Compta Y; Parkinson's Disease and Movement Disorders Unit, Neurology Service, IDIBAPS, CIBERNED (Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas: CB06/05/0018-ISCIII), ERN-RND Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain; Department of Medicine & Institut de Neu
Parkinsonism Relat Disord ; 84: 77-81, 2021 03.
Article em En | MEDLINE | ID: mdl-33581485
INTRODUCTION: The MDS-PSP criteria expand the phenotypic spectrum of PSP by adding to Richardson's syndrome (PSP-RS) other presentations such as PSP-parkinsonism (PSP-P), PSP-pure-gait-freezing (PSP-PGF), PSP-speech-language (PSP-SL), PSP-frontal (PSP-F), PSP-postural-instability (PSP-PI) and PSP-corticobasal-syndrome (PSP-CBS). Evidence about the prognostic differences between PSP phenotypes is scarce and focused on PSP-RS vs. non-PSP-RS. Using a brain-bank cohort we assessed PSP survival not only in PSP-RS vs. non-PSP-RS, but also in PSP-RS + cortical vs. subcortical phenotypes. Besides, we assessed sensitivity and specificity of the MDS-PSP criteria in of PSP and other degenerative parkinsonisms. METHODS: We retrospectively applied the MDS-PSP diagnostic criteria to 32 definite PSP cases and 30 cases with other degenerative parkinsonian syndromes (Parkinson's disease [PD; n = 11], multiple system atrophy [MSA; n = 11], corticobasal degeneration [CBD; n = 8]). We conducted survival statistics in neuropathologically confirmed PSP cases considering PSP-RS vs. non-PSP-RS and PSP-RS + PSP-cortical (PSP-F + PSP-SL + PSP-CBS) vs. PSP-subcortical (PSP-P + PSP-PGF) phenotypes. We also adjusted survival analyses for PSP tau scores. RESULTS: Diagnostic sensitivity was 100% and specificity ranged from 47% to 87% when excluding cases that met the "suggestive of PSP" definition early in their disease course but with other clinical features better matching with a non-PSP pathological diagnosis. Survival was significantly shorter in PSP-RS vs. non-PSP-RS cases, but it was more markedly shorter in PSP-RS + PSP-cortical vs. PSP-subcortical, independently of PSP tau scores, which were not associated with survival. CONCLUSIONS: PSP-subcortical phenotypes appear to have longer survival than PSP-RS and cortical phenotypes. This might be of prognostic relevance when informing patients upon clinical diagnosis.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Paralisia Supranuclear Progressiva / Transtornos Parkinsonianos Tipo de estudo: Diagnostic_studies / Etiology_studies / Guideline / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Parkinsonism Relat Disord Assunto da revista: NEUROLOGIA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Espanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Paralisia Supranuclear Progressiva / Transtornos Parkinsonianos Tipo de estudo: Diagnostic_studies / Etiology_studies / Guideline / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Parkinsonism Relat Disord Assunto da revista: NEUROLOGIA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Espanha